HC Wainwright Brokers Increase Earnings Estimates for CASI

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) – Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of CASI Pharmaceuticals in a report issued on Monday, May 19th. HC Wainwright analyst S. Lee now expects that the biotechnology company will earn ($0.47) per share for the quarter, up from their prior forecast of ($0.60). HC Wainwright currently has a “Buy” rating and a $4.00 price objective on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.57) EPS and FY2029 earnings at ($1.18) EPS.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Friday, May 16th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.08). CASI Pharmaceuticals had a negative net margin of 143.18% and a negative return on equity of 181.52%. The business had revenue of $6.24 million during the quarter, compared to analyst estimates of $7.39 million.

Separately, StockNews.com assumed coverage on CASI Pharmaceuticals in a research report on Wednesday, May 14th. They issued a “hold” rating on the stock.

CASI Pharmaceuticals Stock Performance

Shares of CASI opened at $1.90 on Wednesday. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.81. CASI Pharmaceuticals has a 52-week low of $1.64 and a 52-week high of $7.67. The firm has a market cap of $23.31 million, a price-to-earnings ratio of -0.85 and a beta of 0.81. The company has a quick ratio of 2.32, a current ratio of 3.20 and a debt-to-equity ratio of 1.38.

Institutional Investors Weigh In On CASI Pharmaceuticals

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Woodline Partners LP grew its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 64.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 164,365 shares of the biotechnology company’s stock after acquiring an additional 64,675 shares during the quarter. Woodline Partners LP owned approximately 1.34% of CASI Pharmaceuticals worth $355,000 as of its most recent filing with the Securities and Exchange Commission. 22.23% of the stock is currently owned by institutional investors and hedge funds.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.